Compare LNN & SLDB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | SLDB |
|---|---|---|
| Founded | 1954 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.1B |
| IPO Year | 1995 | 2017 |
| Metric | LNN | SLDB |
|---|---|---|
| Price | $115.09 | $48.95 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | ★ $113.00 | $16.36 |
| AVG Volume (30 Days) | 95.0K | ★ 878.6K |
| Earning Date | 04-02-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.35% | N/A |
| EPS Growth | 12.81 | ★ 34.97 |
| EPS | ★ 4.22 | N/A |
| Revenue | ★ $676,368,000.00 | $8,094,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.74 | N/A |
| P/E Ratio | $27.05 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $97.27 | $3.79 |
| 52 Week High | $148.00 | $11.45 |
| Indicator | LNN | SLDB |
|---|---|---|
| Relative Strength Index (RSI) | 55.02 | 56.51 |
| Support Level | $116.15 | $5.21 |
| Resistance Level | $120.01 | $11.45 |
| Average True Range (ATR) | 2.85 | 0.43 |
| MACD | 0.28 | 0.06 |
| Stochastic Oscillator | 62.89 | 67.25 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.